Literature DB >> 1328241

Responses of pertussis toxin-treated microvascular endothelial cells to transforming growth factor beta 1. No evidence for pertussis-sensitive G-protein involvement in TGF-beta signal transduction.

S A McCarthy1, R Bicknell.   

Abstract

Responses of bovine adrenal capillary endothelial cells (BACE) on treatment with transforming growth factor beta 1 (TGF-beta 1) have been characterized and tested for sensitivity to inactivation of pertussis toxin-sensitive G-proteins. TGF-beta 1 elicited growth inhibition, monolayer remodeling, elevation of steady state mRNA levels for collagen type 1 (alpha 1(1) and alpha 2(1)) and TGF-beta 1, and inhibition of p34cdc2 histone H1 kinase activity in BACE cells. Pertussis toxin treatment enhanced both inhibition of BACE cell [3H]methylthymidine uptake and remodeling of BACE monolayers by TGF-beta 1. These findings contrast with studies of mink lung epithelial cells, in which TGF-beta 1 growth inhibition has been shown to be pertussis-sensitive. Further investigation revealed that pertussis toxin treatment of BACE cells had no effect on TGF-beta 1-stimulated elevation of steady state mRNA levels for collagen type 1 (alpha 1(1) or alpha 2(1)) or for TGF-beta 1. Analysis of p34cdc2 activity in BACE cells revealed potent inhibition of p34cdc2 histone H1 kinase activity by TGF-beta 1. Pertussis toxin treatment also abolished the increase in p34cdc2 activity, however, precluding the determination of the pertussis toxin sensitivity of this response to TGF-beta 1. Consistent with suppression of p34cdc2 activation, pertussis toxin also caused substantial inhibition of mitogen-stimulated BACE cell [3H]methylthymidine uptake. It is concluded that TGF-beta 1 signal transduction in this cell type does not involve G-proteins of the pertussis toxin-sensitive class and that, in view of its potent effects on DNA synthesis and p34cdc2 activation, the use of pertussis toxin to determine G-protein involvement in cytokine signalling pathways should be approached with caution.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328241

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Activation of a serine/threonine kinase signaling pathway by transforming growth factor type beta.

Authors:  A Atfi; K Lepage; P Allard; A Chapdelaine; S Chevalier
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

2.  A slowly ADP-ribosylated pertussis-toxin-sensitive GTP-binding regulatory protein is required for vasopressin-stimulated Ca2+ inflow in hepatocytes.

Authors:  L A Berven; B P Hughes; G J Barritt
Journal:  Biochem J       Date:  1994-04-15       Impact factor: 3.857

3.  Regulation of fibroblast procollagen production. Transforming growth factor-beta 1 induces prostaglandin E2 but not procollagen synthesis via a pertussis toxin-sensitive G-protein.

Authors:  R J McAnulty; R C Chambers; G J Laurent
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

4.  Evidence from studies with hepatocyte suspensions that store-operated Ca2+ inflow requires a pertussis toxin-sensitive trimeric G-protein.

Authors:  K C Fernando; G J Barritt
Journal:  Biochem J       Date:  1994-10-15       Impact factor: 3.857

5.  Expression and hormone regulation of Wnt2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma.

Authors:  T D Bui; L Zhang; M C Rees; R Bicknell; A L Harris
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  High expression of Wnt7b in human superficial bladder cancer vs invasive bladder cancer.

Authors:  T D Bui; T O'Brien; J Crew; D Cranston; A L Harris
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

7.  A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions.

Authors:  P S Braddock; D E Hu; T P Fan; I J Stratford; A L Harris; R Bicknell
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.